Incyte to buy Vega in $2B hematology push

Incyte is buying Vega Therapeutics for up to $2 billion to expand the company's hematology portfolio, the company announced Monday.

Follow the money: Incyte will pay $1.25 billion upfront and commit up to $750 million in sales milestones for the Star Therapeutics subsidiary.